Cointime

EnClear Therapies

company

About

EnClear Therapies is a biotechnology company developing device-based therapies for the treatment of neurodegenerative disease

  • 1 - 10

Highlights

Total Funding Amount
$12M
Funding Rounds
2
Investors
2

Details

Last Funding Type
Series A
Last Funding Money Raised
$10M
Industries
Biotechnology,Therapeutics
Founded date
Jan 1, 2018
Number Of Employee
1 - 10
Operating Status
Active

EnClear Therapies is a Cambridge (USA) based life sciences company developing a device-based therapy to aid in the treatment of neurodegenerative disease and delivery and monitoring of cerebrospinal fluid (CSF). EnClear’s proprietary therapeutic platform focuses on removing toxic proteins from the CSF. The company’s first products will target improving the lives of patients with Amyotrophic Lateral Sclerosis (ALS) and Progressive Supranuclear Palsy (PSP).

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$12M
EnClear Therapies has raised a total of $12M in funding over 2 rounds. Their latest funding was raised on Feb 19, 2020 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 19, 2020 Series A $10M 1 — — Detail
Mar 14, 2019 Seed $2M 1 — — Detail

Investors

Number of Lead Investors
Number of Investors
—
2
EnClear Therapies is funded by 2 investors. Global health sciences venture fund and Sanford Biosciences are the most recent investors.
Investor Name Lead Investor Funding Round
Global health sciences venture fund — Series A
Sanford Biosciences — Seed
Cointime
Chủ Đề
Công Ty